CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VBI Vaccines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VBI Vaccines Inc
222 3rd St Ste 2241
Phone: (617) 830-3031p:617 830-3031 CAMBRIDGE, MA  02142-1259  United States Fax: (302) 636-5454f:302 636-5454

This company ceased filing statements with the SEC on 5/16/2016.
On 5/6/2016, the Company was acquired by SciVac Therapeutics Inc. As a result of the acquisition, SciVac Therapeutics Inc. changed its name to VBI Vaccines Inc.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
VBI Vaccines Inc. is a pharmaceutical company. The Company is engaged in developing various technologies that focus on vaccine protection. The Company has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. Its technology enables the synthetic manufacture of an eVLP. Its Lipid Particle Vaccine technology is a vaccine formulation technology that enables the thermostabilization of vaccines. The technology is constituted by approximately three lipids, such as monopalmitoylglycerol, dihexadecyl phosphate and cholesterol.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201512/31/2015YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Steven H.Gillis 63 7/25/2014 7/25/2014
Chief Executive Officer, Director Jeff R.Baxter 53 9/1/2009 9/1/2009
Chief Financial Officer EgidioNascimento 48 5/1/2014 5/1/2014
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Paulson Capital Properties, LLC
Paulson Investment Company, Inc.
VBI Vaccines
VBIV

General Information
Number of Employees: 60 (As of 12/31/2012)
Outstanding Shares: 26,492,930 (As of 3/22/2016)
Shareholders: 388
Stock Exchange: NASD
Federal Tax Id: 930589534
Fax Number: (302) 636-5454


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 24, 2019